Activation of platelets induced by mAb P256 specific for glycoprotein IIb-IIIa. Possible evidence for a role for IIb-IIIa in membrane signal transduction.
Monoclonal antibody P256, which is specific for glycoprotein IIb-IIIa complex, was found to induce aggregation of normal platelets in plasma. The mechanism of platelet activation induced by this monoclonal antibody was thoroughly studied. The divalent binding to the IIb-IIIa molecule was necessary for triggering aggregation since Fab' fragments did not induce aggregation as did IgG and F(ab')2 fragments; however, F(ab')2 did not induce the release as did the whole IgG. P256-induced aggregation was accompanied by release of all three granule constituents, namely dense granules, alpha-granules and lysosomes, with parallel kinetics showing half-maximum release 50 s after addition of P256. Thromboxane synthesis was initiated at the same time. Using 32P-prelabeled platelets, no variation in level of [32P]phosphatidylinositol 4,5-bisphosphate could be detected in the first minute after P256 addition, indicating no activation of the calcium-independent phospholipase C specific for polyphosphoinositol phospholipid. P256 induced a calcium mobilization as measured by Indo-1 fluorescence of about the third of that measured in the presence of a thrombin concentration giving the same intensity of aggregation. P256 induced phosphorylation of the myosin light chain p20 and of the main substrate of protein kinase C, p43. Addition of aspirin inhibited almost totally calcium mobilization and partially aggregation, release and protein phosphorylations. By contrast, in the absence of external calcium, although no aggregation could occur, the release reaction was only partially reduced. In this activation, the glycoprotein IIb-IIIa complex thus appears to play a role in modulating platelet response, not only via calcium fluxes but also in activating protein kinase C responsible for p43 phosphorylation.
Bachelot
C
C
Unité 150 Institut National de la Santé et de la Recherche Médicale, Hôpital Lariboisière, Paris, France.
Rendu
F
F
Boucheix
C
C
Hogg
N
N
Levy-Toledano
S
S
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology; D001345:Autoradiography; D001665:Binding Sites / Q000502:physiology; D002118:Calcium / Q000378:metabolism / Q000494:pharmacology; D007074:Immunoglobulin G / Q000494:pharmacology; D051379:Mice; D010712:Phosphatidic Acids / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism; D010766:Phosphorylation; D010974:Platelet Aggregation / Q000187:drug effects*; D010980:Platelet Membrane Glycoproteins / Q000276:immunology / Q000502:physiology*; D015398:Signal Transduction / Q000502:physiology*; D013931:Thromboxanes / Q000096:biosynthesis
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D010712:Phosphatidic Acids; D010743:Phospholipids; D010980:Platelet Membrane Glycoproteins; D013931:Thromboxanes; D001241:Aspirin; D002118:Calcium